All studies
Phase 2RecruitingInterventionalNCT06932263

Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids (Umbriel)

A Phase IIb, Multicentre, Double-blind, Placebo-controlled Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adult Participants With Uncontrolled Asthma on Medium-to High Dose Inhaled Corticosteroids

  • Asthma
I want to take partRefer a patient10 sites in India (6 recruiting) · 223 worldwide

At a glance

Phase
Phase 2
Study type
Interventional
Sponsor
AstraZeneca
Enrolment target
540
Started
26 March 2025
Main results due (estimated)
7 June 2027
Study ends (estimated)
28 February 2028
Allocation
Randomized
Design
Parallel
Purpose
Treatment
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Sites
223 · 10 in India
First posted
17 April 2025
Registry updated
30 October 2026

This is a parallel-group treatment study with 3 arms. Participants will be randomised in a ratio of 1:1:1 to one of the 3 treatment arms.

Can you take part?

  • Ages 18 years to 75 years.
  • Open to any sex.
  • You need the condition being studied. Healthy volunteers are not accepted.

Age groups: adult, older adult.

These are the headline rules. Every study has a longer list, and whether you are eligible is decided by the research team at the site, never by this page.

Read the full eligibility criteria
Inclusion Criteria:

1. Provision of signed and dated written informed consent prior to any study-specific procedures.
2. Adults aged 18-75, inclusive when signing the informed consent.
3. Documented physician-diagnosis of asthma for at least 12 months.
4. Treated with medium or high dose ICS in combination with LABA.
5. Demonstration of uncontrolled asthma through ACQ-6 score ≥ 1.5 .
6. Pre-bronchodilator FEV1 ≥ 40% to ≤ 90% of predicted normal.
7. Documented exacerbation history in the last 12 months and biomarker requirements of:

   1. ≥ 2 severe exacerbations OR
   2. 1 severe exacerbation and:

   (i) Eosinophils ≥ 150 cells/µl or (ii) FeNo ≥ 25 ppb
8. Participants need to demonstrate a ≥70% compliance for Asthma Daily Diary.
9. Women of Child Bearing Potential (WOCBP) must have a negative pregnancy test.
10. Contraceptive use by males and females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Exclusion Criteria:

1. Completed treatment for respiratory infection with antibiotics in the 4 weeks prior to Visit 1.
2. Clinically significant pulmonary disease other than asthma .
3. Current smokers, former smokers with \>10 pack-years history.
4. Clinically significant aortic stenosis or pulmonary arterial hypertension.
5. Active tuberculosis, hepatitis, HIV, or current diagnosis of cancer or immune complex disease.
6. Unstable cardiovascular disorders.

What this study is about

In the sponsor’s own words, from the registry.

This is a dose-range finding, double-blind, placebo-controlled, phase IIb study designed to assess efficacy and safety of tozorakimab administered subcutaneously in adult participants with uncontrolled asthma receiving medium-to-high dose inhaled corticosteroids.

What participants receive

  • Experimental

    Tozorakimab Dose 1

    Dosing subcutaneously tozorakimab Dose 1

    Drug: Tozorakimab

  • Experimental

    Tozorakimab Dose 2

    Dosing subcutaneously tozorakimab Dose 2 and placebo

    Drug: Tozorakimab

  • Placebo comparator

    Placebo

    Dosing subcutaneously with equivalent volume to tozorakimab

    Drug: Placebo

Interventions

  • TozorakimabDrug

    The drug will be administered subcutaneously.

  • PlaceboDrug

    Placebo will be administered subcutaneously.

What the study measures

Primary outcomes

  1. Annualised rate of severe asthma exacerbations

    The rate ratio of severe asthma exacerbations will be assessed in the participants with uncontrolled moderate-to-severe asthma and ≥ 1 severe exacerbation within 12 months prior to screening.

    Time frame: Over 26 to 52 weeks

Secondary outcomes

  1. Annualised rate of severe asthma exacerbations

    The rate ratio of severe asthma exacerbations will be assessed in the participants with uncontrolled moderate-to-severe asthma and baseline eosinophils \< 300 cells/µL and history of ≥2 severe exacerbations within 12 months prior to screening.

    Time frame: Over 26 to 52 weeks

  2. Time to first severe asthma exacerbation

    To evaluate the effect of two dose levels of tozorakimab compared to placebo on time to first severe asthma exacerbations.

    Time frame: Over 26 to 52 weeks

  3. Change from baseline in pre-bronchodilator forced expiratory volume in 1 second (FEV1)

    Difference in mean change from baseline between tozorakimab and placebo.

    Time frame: Over weeks 20 to 26

  4. Change from baseline in post-bronchodilator FEV1

    Difference in mean change from baseline between tozorakimab and placebo.

    Time frame: At week 26

  5. Change from baseline in the Asthma Control Questionnaire 6 (ACQ-6)

    Difference in mean change from baseline between tozorakimab and placebo. The ACQ-6 has 6 questions (regarding asthma symptoms and rescue bronchodilator use). Answering the questions results in a score out of 6. A Score of 0 indicates complete control and 6 reflects severely uncontrolled disease.

    Time frame: At week 26

  6. Change from baseline in the Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ12+)

    Difference in mean change from baseline between tozorakimab and placebo. The AQLQ12+ includes 32 questions grouped into four domains: symptoms; activity limitations; emotional function; and, environmental stimuli. Each question is scored on a seven-point Likert scale, which ranges from 7 (no impairment) to 1 (severe impairment). The overall score is calculated as the mean of all questions, and the four domain scores are the means of the scores for the questions in the respective domains.

    Time frame: At week 26

  7. Trough serum concentrations of tozorakimab

    Pharmacokinetics: concentrations of tozorakimab in trough serum.

    Time frame: Over 52 weeks

  8. Anti-drug antibody incidence

    Immunogenicity: Number of Participants With Positive Antibodies to tozorakimab

    Time frame: Over 52 weeks

Who is running it

Lead sponsor
AstraZeneca
Sponsor type
Industry
Responsible party
The sponsor
Organisation
AstraZeneca
Data monitoring committee
Yes
US FDA-regulated drug
Yes
US FDA-regulated device
No
Sponsor's study ID
D9181C00002
Other IDs
2024-519116-14-00

Study sites(223)

  • Research Site

    Belagavi, India

    Recruiting

  • Research Site

    Coimbatore, India

    Recruiting

  • Research Site

    Dehradun, India

    Recruiting

  • Research Site

    Delhi, India

    Recruiting

  • Research Site

    New Delhi, India

    Recruiting

  • Research Site

    Vadodara, India

    Recruiting

  • Research Site

    Lucknow, India

    Suspended

  • Research Site

    Faridabad, India

    Withdrawn

  • Research Site

    Gūrgaon, India

    Withdrawn

  • Research Site

    Kochi, India

    Terminated

  • Research Site

    Bakersfield, California, United States

    Recruiting

  • Research Site

    Long Beach, California, United States

    Recruiting

  • Research Site

    Newport Beach, California, United States

    Recruiting

  • Research Site

    San Jose, California, United States

    Recruiting

  • Research Site

    Noblesville, Indiana, United States

    Recruiting

  • Research Site

    Hutchinson, Kansas, United States

    Recruiting

  • Research Site

    Louisville, Kentucky, United States

    Recruiting

  • Research Site

    Worcester, Massachusetts, United States

    Recruiting

  • Research Site

    Farmington Hills, Michigan, United States

    Recruiting

  • Research Site

    Grand Island, Nebraska, United States

    Recruiting

  • Research Site

    Omaha, Nebraska, United States

    Recruiting

  • Research Site

    Mullica Hill, New Jersey, United States

    Recruiting

  • Research Site

    Toms River, New Jersey, United States

    Recruiting

  • Research Site

    Horseheads, New York, United States

    Recruiting

  • Research Site

    Maspeth, New York, United States

    Recruiting

  • Research Site

    Kings Mountain, North Carolina, United States

    Recruiting

  • Research Site

    Toledo, Ohio, United States

    Recruiting

  • Research Site

    Medford, Oregon, United States

    Recruiting

  • Research Site

    Portland, Oregon, United States

    Recruiting

  • Research Site

    Philadelphia, Pennsylvania, United States

    Recruiting

  • Research Site

    Smithfield, Pennsylvania, United States

    Recruiting

  • Research Site

    Rock Hill, South Carolina, United States

    Recruiting

  • Research Site

    Austin, Texas, United States

    Recruiting

  • Research Site

    Boerne, Texas, United States

    Recruiting

  • Research Site

    Dallas, Texas, United States

    Recruiting

  • Research Site

    El Paso, Texas, United States

    Recruiting

  • Research Site

    Greenville, Texas, United States

    Recruiting

  • Research Site

    Kingwood, Texas, United States

    Recruiting

  • Research Site

    Sugar Land, Texas, United States

    Recruiting

  • Research Site

    Victoria, Texas, United States

    Recruiting

Showing 40 of 223 sites. 144 recruiting, 39 not recruiting and 40 cancelled; 10 in India. Not recruiting covers sites not yet open, finished enrolling, completed or paused; cancelled covers sites withdrawn before opening or stopped for good.

References and data sharing

Participant data shared
Yes
What is shared
Study protocol, Sap
When
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Source: ClinicalTrials.gov record NCT06932263, status verified October 2026. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.

Take part

Interested in this study?

Tell us how to reach you and we will connect you with the study team. Or refer someone you care for, with their permission.

A person reads this, not a bot. We are not doctors, this is not medical advice, and it is not for emergencies.

Not the right study?

Every study recruiting in India, one search away.